Ipsen Receives Positive CHMP Opinion Recommending Cabometyx in Combination With Opdivo as First-line Treatment for Patients Living With Advanced Renal Cell Carcinoma
1
1
Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life and a lower rate of discontinuation versus sunitinib
2,3
Regulatory News:
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for Cabometyx (cabozantinib) in combination with Bristol Myers Squibb s Opdivo (nivolumab) for the first-line treatment of advanced renal cell carcinoma (aRCC). The European Commission, which has the authority to approve medicines for the European Union (E.U.), will now review the CHMP recommendation and a final decision on the application in the E.U. is expected in the coming months.
Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Takeda launches mobile application to support patient for treatment of genetic diseases By siliconindia | Friday, 26 February 2021, 12:16 Hrs Takeda India, part of the Takeda Pharmaceutical Company Limited, a global values-based, R&D-driven biopharmaceutical leader, launched the XPERT EASE application. The application is developed for the exclusive use of healthcare professionals to address awareness-related challenges and enable an efficient digital ecosystem for disease updates and dose calculation for improved management of patients with rare lysosomal storage disorders Doctors screening, diagnosis, and treatment of genetic diseases have often been identified as challenging, including advising the dosage of medicines specific to patients individual needs. The XPERT EASE is designed to keep in mind such challenges while managing lysosomal storage disorders.
Published: Feb 26, 2021
GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.
“This agreement progresses our collaboration with Takeda as we rapidly work together to make our vaccine candidate available in Japan,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “It is vital that we extend the reach and availability of vaccines like NVX-CoV2373 to stop th
Takeda launches mobile app for management of genetic diseases biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.